State-of-the-Art Nanopharmaceutical Drug Delivery Platforms for Antineoplastic Agents
Pp. 282-368 (87)
Georgi Ts. Momekov, Denitsa B. Momekova, Plamen T. Peykov and Nikolay G. Lambov
The anticancer agents share the distinction of having the lowest therapeutic
indices among clinically utilized drug classes and hence antineoplastic chemotherapy is
associated with dose-limiting toxicities. Moreover, many of the cytotoxic agents are
characterized with pharmacokinetic problems, e.g., limited stability, fast elimination
and low level of tissue penetration, further limiting their usefulness. The advances in
our understanding of the tumor biology and microenvironment characteristics and the
evolvement of nano-sized systems, suitable as drug-delivery platforms have conditioned
immense research interest towards design and elaboration of tumor-targeted nano
carriers. Based on the possibilities for ensuring tumor- or organ targeted delivery and
triggered or controlled release nanocarriers allow for augmented and sustained
anticancer activity of loaded agents, with a concomitant decreased systemic exposure
and toxicity. Moreover, nano-carriers could also aid for improvement of the
biopharmaceutical, stability and solubility characteristics of encapsulated drugs. The
presented review gives a concise outline of the liposomes, polymeric micelles and
related polymeric carriers, and molecular hosts as anticancer drug delivery platforms.
Antineoplastic agents, targeted drug delivery, EPR effect, PEG,
liposomes, nanoparticles, polymeric micelles, dendrimers, molecular hosts.
Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, MU-Sofia, Bulgaria.